GlassScriptPhysician profile
Matthew J Timm
NPI 1952345167
$1,911.52
in general payments reported to CMS, 2019-2025
28 companies · $335 in 2025
The $335 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $205 · 2020: $76.46 · 2021: $198 · 2022: $367 · 2023: $573 · 2024: $157 · 2025: $335.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,065.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,065.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $411.54 | 2022-2025 | Ubrelvy, Vraylar, Qulipta |
| Amgen INC. | $254.11 | 2019-2022 | |
| Pfizer INC. | $153.73 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $148.96 | 2019-2024 | |
| Philips North America LLC | $134.07 | 2022 | |
| Abbott Laboratories | $111.12 | 2023 | Proclaim |
| Otsuka America Pharmaceutical, INC. | $104.01 | 2022-2023 | Rexulti |
| Astellas Pharma US INC | $59.60 | 2023-2025 | Veozah, Myrbetriq |
| Astrazeneca Pharmaceuticals LP | $58.00 | 2021-2025 | Airsupra, Breztri |
| Novo Nordisk INC | $56.27 | 2019-2025 | Ozempic |
| Mylan Specialty L.P. | $42.30 | 2019-2023 | Yupelri |
| Ultragenyx Pharmaceutical INC. | $41.09 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $39.50 | 2019-2021 | |
| Lilly USA, LLC | $32.90 | 2023-2025 | Jardiance, Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $30.10 | 2022-2023 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $28.00 | 2021-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Inspire Medical Systems, INC. | $27.10 | 2025 | Inspire |
| E.R. Squibb & Sons, L.L.C. | $23.94 | 2021-2022 | |
| Ascensia Diabetes Care US INC. | $19.90 | 2020 | |
| Allergan, INC. | $19.00 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.40 | 2023 | Gattex |
| Amarin Pharma, INC. | $16.16 | 2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.05 | 2025 | Caplyta |
| Biohaven Pharmaceuticals, INC. | $14.15 | 2021 | |
| Merck Sharp & Dohme LLC | $13.84 | 2023 | Vaxneuvance, Vaxelis, Gardasil 9 |
| Boston Scientific Corporation | $13.26 | 2023 | Watchman Access System |
| Sanofi Pasteur INC. | $12.90 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $12.52 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Timm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.